Publication at Faculty of Medicine in Hradec Králové |
2015
Abstract
Golimumab, a fully human TNF-alpha blocker, represents high-quality treatment of ankylosing spondylitis with activity unmanageable standard treatment. Its advantage is the applications once a month s.c. you can use it with very good effect even after the secondary failure of another TNF blocker.